Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

Item

http://www.wikidata.org/entity/Q38916421

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

@en

type

Item

label

Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

@en

prefLabel

Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

@en

P1476

Management of Juvenile Idiopathic Arthritis: A Clinical Guide.

@en

P2093

Gašper Markelj

http://www.w3.org/2001/XMLSchema#string

Mojca Zajc Avramovič

http://www.w3.org/2001/XMLSchema#string

Nataša Toplak

http://www.w3.org/2001/XMLSchema#string

Štefan Blazina

http://www.w3.org/2001/XMLSchema#string

P2860

Sulfasalazine for ankylosing spondylitis

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Current treatment of juvenile rheumatoid arthritis.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

P2888

s40272-016-0186-0

P304

397-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40272-016-0186-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tadej Avčin

P577

2016-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052356801

http://www.w3.org/2001/XMLSchema#string

P698

27484749

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis